Clinical Trials Logo

Clinical Trial Summary

This study is being done to find out if zanidatamab when given with ALX148 is safe and can treat patients with advanced (locally advanced [inoperable] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.

Clinical Trial Description

Part 1 of the study will first evaluate the safety and tolerability and establish the recommended doses (RDs) of zanidatamab in combination with ALX148. Part 2 of the study will evaluate the anti-tumor activity of the combination of zanidatamab plus ALX148 at the RD levels in indication-specific expansion cohorts. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05027139
Study type Interventional
Source Zymeworks Inc.
Contact Zymeworks Clinical Trial Resource
Phone (206) 237-1030
Email [email protected]
Status Recruiting
Phase Phase 1/Phase 2
Start date September 2021
Completion date June 2025

See also
  Status Clinical Trial Phase
Recruiting NCT02892123 - Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers Phase 1
Recruiting NCT03821233 - A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers Phase 1